Abemaciclib for HR-Positive Metastatic Breast Cancer
1 Views
administrator
07/03/23
Adam M. Brufsky, MD, PhD, FACP; Komal Jhaveri, MD, FACP; Lee Schwartzberg, MD, FACP; Hope S. Rugo, MD; and Francisco Esteva, MD, PhD, discuss the use of abemaciclib in metastatic hormone receptor-positive breast cancer, the management of toxicity, and resistance mechanisms to CDK4/6 inhibitors.
-
Category
Show more
Facebook Comments
No comments found